kestine 20 mg apvalkotās tabletes
almirall, s.a., spain - ebastīns - apvalkotā tablete - 20 mg
kestine 10 mg apvalkotās tabletes
almirall, s.a., spain - ebastīns - apvalkotā tablete - 10 mg
kestine 10 mg apvalkotās tabletes
almirall, s.a., spain - ebastīns - apvalkotā tablete - 10 mg
cladosol 100 mg cietās kapsulas
stada arzneimittel ag, germany - itrakonazols - kapsula, cietā - 100 mg
itraconazol actavis 100 mg cietās kapsulas
teva b.v., netherlands - itrakonazols - kapsula, cietā - 100 mg
ofloxin 200 mg apvalkotās tabletes
zentiva, k.s., czech republic - ofloksacīns - apvalkotā tablete - 200 mg
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiski līdzekļi - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
itranols 100 mg cietās kapsulas
olainfarm, as, latvia - itrakonazols - kapsula, cietā - 100 mg
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiski līdzekļi - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.
ketoconazole hra
hra pharma rare diseases - ketokonazols - cushing sindroms - antimycotics sistēmiskai lietošanai - ketokonazola hra indicēts endogēna kušinga sindroma ārstēšanai pieaugušajiem un pusaudžiem vecumā virs 12 gadiem.